Related Experiment Video
Updated: Jul 10, 2026

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload
Published on: March 14, 2017
Blood donors and the challenges in supplying blood products and factor concentrates
1Department of Medicine, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
Voluntary blood donors are the source of all red cell, platelet, and unprocessed plasma products used in clinical medicine. Paid donors provide most of the raw plasma used in commercially processed plasma products, such as albumin and intravenous gamma globulin. Each year, less than 5% of the population donates blood, and almost half the units come from 1% of the population who are frequent donors. Pressures that affect the number of potential donors include changing demography and motivation. Pressures that affect the suitability of potential donors include endemic and emerging infectious diseases, drug and vaccine use, and behavioral factors. The net result of these pressures is increasing difficulty in finding enough acceptable donors. Demands on the current blood supply leave few resources and raw materials available for the development of newer, safer, and more effective therapeutic products. The development of recombinant coagulation proteins reduces the pressure on this limited supply of donated plasma, and reducing bleeding protects the supply of cellular blood and plasma-derived products.
Voluntary blood donors are the source of all red cell, platelet, and unprocessed plasma products used in clinical medicine. Paid donors provide most of the raw plasma used in commercially processed plasma products, such as albumin and intravenous gamma globulin. Each year, less than 5% of the population donates blood, and almost half the units come from 1% of the population who are frequent donors. Pressures that affect the number of potential donors include changing demography and motivation. Pressures that affect the suitability of potential donors include endemic and emerging infectious diseases, drug and vaccine use, and behavioral factors. The net result of these pressures is increasing difficulty in finding enough acceptable donors. Demands on the current blood supply leave few resources and raw materials available for the development of newer, safer, and more effective therapeutic products. The development of recombinant coagulation proteins reduces the pressure on this limited supply of donated plasma, and reducing bleeding protects the supply of cellular blood and plasma-derived products.
More Related Videos
Related Concept Videos
Blood Transfusion and Agglutination
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
Blood Transfusion
Blood Transfusion Overview
A blood transfusion is a medical procedure used to replace blood lost due to injury, surgery, or to treat conditions such as anemia or cancer. During a transfusion, donor blood is...
Factors Affecting Erythropoiesis
Several factors influence the erythrocyte production rate, with tissue oxygen level being among the most critical. Intense exercise or high altitudes can cause tissue hypoxia, which triggers the kidneys to release more erythropoietin (EPO) into the bloodstream.
EPO then...
Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
Rh Blood Group
Role of Hematopoietic Growth Factors
Thrombopoietin (TPO), mainly released by the liver,...

